drugset / Trial / NCT00624481

Study to Evaluate Effect of Intranasal Teriparatide on Bone Mineral Density in Postmenopausal Women With Low BMD

NCT00624481

Phase 2 Withdrawn 350 enrolled Nastech Pharmaceutical Company, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is being conducted to compare the effect of increasing nasal teriparatide dosing on percent change in Bone Mineral Density (BMD) of the lumbar spine after 24 weeks of therapy in postmenopausal women with low bone mineral density.

Timeline

Start
2008-03
Primary completion
2009-04
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Teriparatide Protein / enzyme biologic 20 ug Subcutaneous

Indications